Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients |
Chien, Tsu-Ming
(Department of Urology, Kaohsiung Medical University Hospital)
Lu, Yen-Man (Department of Urology, Kaohsiung Medical University Hospital) Geng, Jiun-Hung (Department of Urology, Kaohsiung Medical University Hospital) Huang, Tsung-Yi (Department of Urology, Kaohsiung Medical University Hospital) Ke, Hung-Lung (Department of Urology, Kaohsiung Medical University Hospital) Huang, Chun-Nung (Department of Urology, Kaohsiung Medical University Hospital) Li, Ching-Chia (Department of Urology, Kaohsiung Medical University Hospital) Chou, Yii-Her (Department of Urology, Kaohsiung Medical University Hospital) Wu, Wen-Jeng (Department of Urology, Kaohsiung Medical University Hospital) Huang, Shu-Pin (Department of Urology, Kaohsiung Medical University Hospital) |
1 | Singh D, Yi WS, Brasacchio RA, et al (2004). Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys, 58, 3-10. DOI |
2 | Soloway MS, Hardeman SW, Hickey D, et al (1988). Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195-202. DOI |
3 |
Tanaka N, Fujimoto K, Shinkai T, et al (2011). Bone scan can be spared in asymptomatic prostate cancer patients with PSA of |
4 | Young CY, Montgomery BT, Andrews PE, et al (1991). Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res, 51, 3748-52. |
5 | Bashir MN, Ahmad MR, Malik A (2014). Risk factors of prostate cancer: a case-control study in Faisalabad, Pakistan. Asian Pac J Cancer Prev, 15, 10237-40. |
6 | Briganti A, Passoni N, Ferrari M, et al (2010). When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol, 57, 551-8. DOI |
7 | Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007). Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol, 178, S14-9. DOI |
8 | Dennis ER, Jia X, Mezheritskiy IS, et al (2012). Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol, 30, 519-24. DOI |
9 | Drzymalski DM, Oh WK, Werner L, et al (2010). Predictors of survival in patients with prostate cancer and spinal metastasis. presented at the 2009 joint spine section meeting. clinical article. J Neurosurg Spine, 13, 789-94. DOI |
10 | Falchook AD, Salloum RG, Hendrix LH, Chen RC (2014). Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys, 89, 243-8. DOI |
11 | Greene KL, Albertsen PC, Babaian RJ, et al (2009). Prostate specific antigen best practice statement: 2009 update. J Urol, 182, 2232-41. DOI |
12 | Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q (2014). Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. PLoS One, 9, 106677. DOI |
13 | Harada M, Iida M, Yamaguchi M, Shida K (1992). Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol, 324, 173-82. DOI |
14 | He D, Wang M, Chen X, et al (2004). Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population. Urol, 63, 722-6. DOI |
15 | Heidenreich A, Bastian PJ, Bellmunt J, et al (2014). European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol, 65, 124-37. DOI |
16 | Imbriaco M, Larson SM, Yeung HW, et al (1998). A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res, 4, 1765-72. |
17 | Isom-Batz G, Bianco FJ Jr, Kattan MW, et al (2005). Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol, 173, 1935-7. DOI |
18 | Kosuda S, Yoshimura I, Aizawa T, et al (2002). Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer, 94, 964-72. DOI |
19 | Lee N, Fawaaz R, Olsson CA, et al (2000). Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys, 48, 1443-6. DOI |
20 | Logothetis CJ, Lin SH (2005). Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer, 5, 21-8. DOI |
21 | National Comprehensive Cancer Network Guidelines (2014). Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. |
22 | Morgentaler A, Bruning CO 3rd, DeWolf WC (1996). Occult prostate cancer in men with low serum testosterone levels. JAMA, 276, 1904-6. DOI |
23 | Nakashima J, Tachibana M, Ueno M, et al (1998). Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res, 4, 1743-8 |
24 | Nandeesha H (2009). Insulin: a novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol, 41, 267-72. DOI |
25 | Oesterling JE, Kumamoto Y, Tsukamoto T, et al (1995). Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol, 75, 347-53. DOI |
26 | Ost P, Decaestecker K, Lambert B, et al (2014). Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate, 74, 297-305. DOI |
27 | Pound CR, Partin AW, Eisenberger MA, et al (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281, 1591-7. DOI |
28 | Sabbatini P, Larson SM, Kremer A, et al (1999). Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol, 17, 948-57. DOI |
29 | Schweizer MT, Zhou XC, Wang H, et al (2013). Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol, 24, 2881-6. DOI |
![]() |